Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
伊布替尼加入标准预处理方案,并作为自体造血干细胞移植后复发或难治性活化B细胞型弥漫性大B细胞淋巴瘤的维持治疗:美国多中心双盲随机III期研究Alliance A051301/BMT-CTN 1201的主要分析
期刊:Leukemia & Lymphoma
影响因子:2.200
doi:10.1080/10428194.2025.2525982
Andreadis, Charalambos; Bobek, Olivia; Hsi, Eric D; Fenske, Timothy S; Stiff, Patrick J; Hill, Brian T; Geyer, Susan M; Horwitz, Mitchell; Khimani, Farhad; Little, Richard F; Dinner, Shira N; Friedberg, Jonathan W; Kahl, Brad S; Perales, Miguel-Angel; Devine, Steven M; Leonard, John P; Bartlett, Nancy L
B细胞
发育与干细胞
淋巴瘤
干细胞
细胞生物学
免疫/内分泌